Different methods of local allergen-specific immunotherapy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 57, Issue 5, 2002, Pages 379-388

  Kagi M K ^a   Wuthrich B ^b  

^a Dermatology Allergy and Immunology FMH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGY; ANTIGEN RECOGNITION; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SENSITIZATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; EPITOPES; HUMANS; HYPERSENSITIVITY; TREATMENT OUTCOME;

EID: 0036242384     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2002.01153.x     Document Type: Review

References (125)

1. Oral tolerance
2. The immunizing cure of hay fever
3. Kuhmilch als ursache von ernährungsstörungen bei säuglingen
4. Oral therapy in ragweed pollinosis, a comparative study
5. Zur peroralen desensibilisierung von inhalationsallergien im kindesalter
6. Orale hyposensibilisierung bei kindern
7. Orale hyposensibilisierung
8. Ergebnisse der subkutanen und oralen spezifischen hyposensibilisierung mit inhalationsallergenen
9. Neuere ergebnisse der peroralen hyposensibilisierung beim kindlichen asthma bronchiale
10. Pollinosis des kindes als prototyp einer atopischen krankheit
11. Orale hyposensibilisierung
12. Zur persorption von pollen und sporen durch die intakte darmschleimhaut
13. Determinants of patient compliance with allergen immunotherapy
14. EAACI immunotherapy position paper
15. Systemic reactions occurring in immunotherapy with standardized pollen extracts
16. A prospective safety monitoring study of immunotherapy with biologically standardized extracts
17. Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen
18. Suppression of IgE responses following inhalation of antigen. A natural homeostatic mechanism which limits sensitization to aeroallergens
19. Suppression of IgE responses by antigen inhalation: Studies on the role of genetic and environmental factors
20. Defence against allergic sensitization in healthy lung: The role of inhalation tolerance
21. The regulation of immune response to dietary proteins
22. Sublingual allergen administration. 1. Selective suppression of IgE production in rats by high allergen doses
23. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
24. Antigen presentation in the murine oral epithelium
25. Langerhans-like dendritic cells generated from cord blood progenitors internalise pollen allergens by macropinocytosis, and part of the molecules are processed and can activate autologous naïve T-lymphocytes
26. Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair
27. Antigen presenting capacity of Langerhans cells from rat oral epithelium
28. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells
29. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4 + T cells
30. Persorption
31. Transport of large breakdown products of dietary protein through the gut wall
32. The biological reactions to the vegetable proteins. I. Anaphylaxis
33. The route of ingested egg white to the systemic circulation
34. Flare-up of antigen-induced arthritis in mice after challenge with oral antigen
35. Enterale resorption grossmolekularer proteine bei tieren und menschen
36. The intestinal mucosal barrier to intact antigenic protein. Difference between colon and small intestine
37. Antigentransport im darm
38. Intestinal permeability in patients with eczema and food allergy
39. Intestinal permeability in atopic eczema
40. Intestinal permeability in healthy and allergic children before and after sodium-cromoglycate treatment assessed with different sized polyethylenglycols (PEG 400 PEG 1000)
41. Small intestinal permeability to sugars in patients with atopic eczema
42. Intestinal permeability and inflammation in rheumatoid arthritis: Effects of non-steroidal anti-inflammatory drugs
43. Mucosal immunity: The origin and migration patterns of cells in the secretory immune system
44. The mucosal immunologic network
45. Der gastrointestinaltrakt als immunorgan: Das darmassoziierte immunsystem
46. Der verdauungstrakt als immunorgan
47. Selective induction of an immune response in human external secretions by ingestion of bacterial antigen
48. Abrogation by subsequent feeding of antibody response, inlcuding IgE, in parenterally immunized mice
49. Changes in specific B-cells and the dissemination of the primed state in vivo following antigenic stimulation by different mucosal routes
50. Enhancement and suppression of the Peyer's patch immune response by systemic priming
51. Local nasal immunotherapy for ragweed-allergic-rhinitis
52. Hypersensitiveness to neoarsphenamine in guinea-pigs: Experiments in prevention and in desensitization
53. Inhibition of experimental drug allergy by prior feeding of the sensitizing antigen
54. Feeding of antigen reduces antigen-binding activity and blunts the secondary response of actively immunized rats
55. Leukocyte histamine release and humoral changes during oral and subcutaneous hyposensitization of grass pollen allergic children
56. Wells and Osborne revisited: Immune tolerance
57. Kinetics of oral tolerance: Study of variables affecting tolerance induced by oral administration of antigen
58. Tolerance, hypersensitivity and the gut in childhood
59. Systemic tolerance and secretory immunity after oral immunization
60. Regulation of ongoing IgE antibody responses with minute doses of antigen
61. The regulation of gastrointestinal immune response
62. Genetic differences in the handling of ingested antigens by the gut
63. Immune regulation in the gastrointestinal tract
64. The role of developmental immune mechanisms in intestinal allergy
65. Immunotherapy and allergic inflammation
66. Mucosal IgA, mucosal cow's milk antibodies, serum cow's milk antibodies and gastrointestinal permeability in infants
67. Allergen standardization and skin test
68. A three-year double blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: Evidence of safety and efficacy in paediatric patients
69. Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitisation treatment of hay fever
70. Local intranasal immunotherapy for ragweed allergic rhinitis. 1. Clinical response
71. Preseasonal intranasal immunotherapy with nebulized short ragweed extract
72. Intranasal immunotherapy and polymerized grass pollen allergens
73. Local intranasal immunotherapy for grass-allergic rhinitis
74. Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts
75. Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study
76. Local nasal immunotherapy for Dermatophagoides-induced rhinitis: Efficacy of a powder extract
77. Nasal immunotherapy to Parietaria: Evidence of reduction of local inflammation
78. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen
79. Local nasal immunotherapy for birch allergic rhinitis with extract in powder form
80. Local nasal immunotherapy with extract in powder form is effective and safe in grass-pollen rhinitis. A double blind study
81. Preseasonal intranasal immunotherapy in birch-alder allergic rhinitis. A double-blind study
82. Local nasal immunotherapy with a powder extract for grass pollen induced rhinitis in pediatric ages: A controlled study
83. Nasal immunotherapy in weed-induced allergic rhinitis
84. Long-term follow-up of nasal immunotherapy to Parietaria: Clinical and local immunological effects. A double-blind study
85. Clinical efficacy and tolerability of a steady dosage schedule of local nasal immunotherapy. Results of preseasonal treatment in grass pollen rhinitis
86. A multicenter trial of specific local nasal immunotherapy
87. Local immunotherapy with Dermatophagoides extract in asthma
88. Immunotherapy by inhalation of allergen in powder in house dust allergic asthma: A double-blind study
89. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children
90. Oral administration of grass pollen to hay fever patients. An efficacy study in oral hyposensitization
91. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study
92. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo controlled study
93. Oral immunotherapy in birch pollen hay fever
94. Safety and efficacy of oral immunotherapy with standardized cat extract
95. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation
96. Efficacy and safety of oral immunotherapy with short ragweed extract
97. WHO Position Paper Allergen immunotherapy. Therapeutic vaccines for allergic diseases
98. In vitro studies of degradation of birch and timothy pollen allergen preparations by human duodenal juice
99. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract
100. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study
101. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: A double-blind, placebo-controlled study
102. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study
103. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis
104. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: A double-blind, placebo-controlled study
105. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: A double-blind, placebo-controlled study
106. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract
107. Clinical efficacy of sublingual-swallow immunotherapy: A double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis
108. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops an sublingual tablets) versus placebo in seasonal rhinitis. A double-blind, randomized, placebo controlled study with 126 patients
109. Sublingual immunotherapy in parietaria pollen induced rhinitis: A double blind study
110. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis
111. Immunotherapy with sublingual birch pollen extract. A short-term double blind placebo study
112. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. A double-blind, randomized, placebo-controlled study with 66 children
113. Safety of sublingual-swallow immunotherapy in children and adults
114. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study
115. Comparative clinical-immunological study of oral and subcutaneous immunotherapy in children with extrinsic bronchial asthma
116. Oral immunotherapy with grass pollen in enterosoluble capsules
117. Local immunotherapy by inhalation of a powder extract in asthma due to house dust mite Dermatophagoides pteronyssinus: A double-blind comparison with parenteral immunotherapy
118. Improvement of fog and exercise induced asthma after local and subcutaneous immunotherapy in mite asthma
119. Bizzaor. Humoral response subcutaneous, oral and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus
120. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients
121. Sublingual versus injective immunotherapy in grass pollen allergic patients: A double blind (double dummy) study
122. Clinical efficacy of sublingual-swallow and subcutaneous immunotherapy in patients with allergic rhinoconjunctivitis due to birch polle. A placebo-controlled, double-blind, double-dummy study
123. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force